Sellas Life Sciences faces high risk in the Phase 3 REGAL AML trial for GPS. Click here to know why I rate the SLS stock a ...

Company to host analyst call at 5:00pm ET today to discuss progress to date and expansion of clinical trial SOUTH SAN FRANCISCO, Calif, Jan. 07, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, ...

Detailed price information for Moleculin Biotech CS (MBRX-Q) from The Globe and Mail including charting and trades.

Combining proteasome inhibitors with autophagy inhibitors disrupts acute myeloid leukemia (AML) cells' proteostasis, enhancing treatment efficacy and inducing programmed cell death. The novel therapy ...